ArcScan

Executive Summary

ArcScan is a U.S.-based medical device company specializing in robotic, very high-frequency ultrasound imaging for the anterior segment of the eye. Its flagship product, the Insight 100, provides detailed anatomical visualization behind the iris, enabling precise surgical planning for refractive, cataract, and glaucoma procedures. Founded in 2005, the company has developed a unique imaging platform that addresses the limitations of traditional optical methods, offering repeatable and high-resolution imaging in clinical settings. By improving visualization of structures like the ciliary body and angle, ArcScan aims to enhance outcomes in anterior segment surgery and diagnostics. The global ophthalmology market increasingly demands advanced imaging to support complex procedures, and ArcScan is well-positioned to capture a niche within this space. With its focus on robotic precision and high-frequency ultrasound, the Insight 100 differentiates itself from competitors such as optical coherence tomography (OCT) and standard ultrasound systems. If successful in scaling commercial adoption and securing regulatory approvals for new indications, ArcScan could transform the standard of care in anterior segment imaging. While the company remains private with limited public financial data, its long history and specialized technology suggest potential for growth as clinical evidence accumulates.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for expanded glaucoma imaging indication60% success
• Q3 2026Partnership with major ophthalmic surgery center network70% success
• Q2 2026Publication of pivotal clinical validation study in peer-reviewed journal80% success